Mundigl; Olaf

Patent Applications and Registrations

Patent applications and USPTO patent grants for Mundigl; Olaf.The latest application filed is for "antibody that binds to vegf and il-1beta and methods of use".

Company Profile

16.39.41

Mundigl; Olaf - Weilheim DE
MUNDIGL; OLAF - PENZBERG DE
Mundigl; Olaf - Weilhem DE
- Weilhem DE
Mundigl; Olaf - Polling DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles Grant 11,273,223 - Brinkmann , et al. March 15, 2	2022-03-15
Antibody That Binds To Vegf And Il-1beta And Methods Of Use App 20220041707 - BECKMANN; ROLAND ; et al.	2022-02-10
Antibody that binds to VEGF and IL-1beta and methods of use Grant 11,130,804 - Beckmann , et al. September 28, 2	2021-09-28
Humanized Anti-tau(ps422) Antibodies And Methods Of Use App 20210139571 - Dengl; Stefan ; et al.	2021-05-13
Bispecific Anti-hapten/anti-blood Brain Barrier Receptor Antibodies, Complexes Thereof And Their Use As Blood Brain Barrier Shuttles App 20210069338 - Brinkmann; Ulrich ; et al.	2021-03-11
Humanized anti-tau(pS422) antibodies and methods of use Grant 10,822,402 - Dengl , et al. November 3, 2	2020-11-03
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles Grant 10,806,795 - Brinkmann , et al. October 20, 2	2020-10-20
Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein App 20200299397 - Barbour; Robin ; et al.	2020-09-24
Bispecific antibodies and methods of use in ophthalmology Grant 10,730,938 - Bedoucha , et al.	2020-08-04
Humanized Anti-tau(ps422) Antibodies And Methods Of Use App 20200223912 - Grueninger; Fiona ; et al.	2020-07-16
Antibody That Binds To Vegf And Il-1beta And Methods Of Use App 20200199214 - BECKMANN; ROLAND ; et al.	2020-06-25
Anti-alpha-synuclein antibodies and methods of use Grant 10,647,761 - Kaluza , et al.	2020-05-12
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles Grant 10,561,737 - Brinkmann , et al. Feb	2020-02-18
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein Grant 10,562,973 - Barbour , et al. Feb	2020-02-18
Bispecific Anti-hapten/anti-blood Brain Barrier Receptor Antibodies, Complexes Thereof And Their Use As Blood Brain Barrier Shut App 20200000929 - Brinkmann; Ulrich ; et al.	2020-01-02
Humanized anti-Tau(pS422) antibodies and methods of use Grant 10,465,000 - Grueninger , et al. No	2019-11-05
Anti-alpha-synuclein Antibodies And Methods Of Use App 20190292248 - Kaluza; Klaus ; et al.	2019-09-26
Anti-IL-1beta antibodies Grant 10,344,085 - Dengl , et al. July 9, 2	2019-07-09
Anti-alpha-synuclein antibodies and methods of use Grant 10,316,082 - Kaluza , et al.	2019-06-11
Humanized anti-Tau(pS422) antibodies and methods of use Grant 10308710 -	2019-06-04
Anti-PDGF-B antibodies and methods of use Grant 10,087,246 - Bedoucha , et al. October 2, 2	2018-10-02
Anti-alpha-synuclein Antibodies And Methods Of Use App 20180237510 - KALUZA; Klaus ; et al.	2018-08-23
Humanized Anti-tau(ps422) Antibodies And Methods Of Use App 20180079804 - Dengl; Stefan ; et al.	2018-03-22
Anti-alpha-synuclein antibodies and methods of use Grant 9,890,209 - Kaluza , et al. February 13, 2	2018-02-13
Humanized anti-tau(pS422) antibodies and methods of use Grant 9,862,763 - Dengl , et al. January 9, 2	2018-01-09
Anti-alpha-synuclein Antibodies And Methods Of Use App 20170327566 - Kaluza; Klaus ; et al.	2017-11-16
Anti-pdgf-b Antibodies And Methods Of Use App 20170247440 - Bedoucha; Marc ; et al.	2017-08-31
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE App 20170247447 - Dengl; Stefan ; et al.	2017-08-31
Bispecific Antibodies And Methods Of Use In Ophthalmology App 20170240629 - Bedoucha; Marc ; et al.	2017-08-24
Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein App 20170174777 - Barbour; Robin ; et al.	2017-06-22
Anti-alpha-synuclein antibodies and methods of use Grant 9,670,274 - Kaluza , et al. June 6, 2	2017-06-06
HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE App 20170129949 - Grueninger; Fiona ; et al.	2017-05-11
Anti-alpha-synuclein Antibodies And Methods Of Use App 20170114123 - Kaluza; Klaus ; et al.	2017-04-27
Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent Grant 9,574,016 - Brinkmann , et al. February 21, 2	2017-02-21
Humanized anti-Tau(pS422) antibodies and methods of use Grant 9,562,091 - Grueninger , et al. February 7, 2	2017-02-07
HUMANIZED ANTI-TAU(pS422) ANTIBODIES AND METHODS OF USE App 20160376352 - Dengl; Stefan ; et al.	2016-12-29
Anti-alpha-synuclein antibodies and methods of use Grant 9,493,553 - Kaluza , et al. November 15, 2	2016-11-15
Biospecific Anti-hapten/anti-blood Brain Barrier Receptor Antibodies, Complexes Thereof And Their Use As Blood Brain Barrier Shuttles App 20160324984 - Brinkmann; Ulrich ; et al.	2016-11-10
Anti-MCSP antibodies Grant 9,309,306 - Freytag , et al. April 12, 2	2016-04-12
Use of an anti-Tau pS422 antibody for the treatment of brain diseases Grant 9,290,567 - Bohrmann , et al. March 22, 2	2016-03-22
Complex Of Bi-specific Antibody And Digoxigenin Conjugated To A Therapeutic Or Diagnostic Agent App 20160009823 - Brinkmann; Ulrich ; et al.	2016-01-14
Antibodies against human EPO receptor Grant 9,221,909 - Jarsch , et al. December 29, 2	2015-12-29
Anti-human EPO receptor antibodies and methods of use Grant 9,187,563 - Jarsch , et al. November 17, 2	2015-11-17
HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE App 20150175685 - Grueninger; Fiona ; et al.	2015-06-25
Bi-specific digoxigenin binding antibodies Grant 9,050,375 - Bramlage , et al. June 9, 2	2015-06-09
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE App 20150140003 - Kaluza; Klaus ; et al.	2015-05-21
Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent Grant 8,907,069 - Brinkmann , et al. December 9, 2	2014-12-09
Anti-human Epo Receptor Antibodies And Methods Of Use App 20140193418 - Jarsch; Michael ; et al.	2014-07-10
Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies Grant 8,623,666 - Jarsch , et al. January 7, 2	2014-01-07
Use of an anti-Tau pS422 antibody for the treatment of brain diseases Grant 8,609,097 - Bohrmann , et al. December 17, 2	2013-12-17
Use Of An Anti-tau Ps422 Antibody For The Treatment Of Brain Diseases App 20130310541 - Bohrmann; Bernd ; et al.	2013-11-21
Anti-mcsp Antibodies App 20130078251 - Freytag; Olivier ; et al.	2013-03-28
Anti-human Epo Receptor Antibodies And Methods Of Use App 20120321633 - Jarsch; Michael ; et al.	2012-12-20
Bi-specific Digoxigenin Binding Antibodies App 20120282280 - Bramlage; Birgit ; et al.	2012-11-08
Complex Of Bi-specific Antibody And Digoxigenin Conjugated To A Therapeutic Or Diagnostic Agent App 20120269723 - Brinkmann; Ulrich ; et al.	2012-10-25
Antibodies Against Human Epo Receptor App 20120122120 - Jarsch; Michael ; et al.	2012-05-17
Antibodies Against Human Epo Receptor App 20110165592 - Jarsch; Michael ; et al.	2011-07-07
Antibodies Against Human Epo Receptor App 20110143372 - Jarsch; Michael ; et al.	2011-06-16
Use Of An Anti-tau Ps422 Antibody For The Treatment Of Brain Diseases App 20110059093 - Bohrmann; Bernd ; et al.	2011-03-10
Antibodies Against Insulin-like Growth Factor I Receptor And Uses Thereof App 20090275126 - Graus; Yvo ; et al.	2009-11-05
Antibody selection method against IGF-IR Grant 7,579,157 - Graus , et al. August 25, 2	2009-08-25
Antibodies against insulin-like growth factor I receptor and uses thereof Grant 7,572,897 - Graus , et al. August 11, 2	2009-08-11
Antibodies Against Insulin-like Growth Factor I Receptor And Uses Thereof App 20080132686 - Graus; Yvo ; et al.	2008-06-05
Antibodies against insulin-like growth factor 1 receptor and uses thereof Grant 7,378,503 - Graus , et al. May 27, 2	2008-05-27
Thiophene hydroxamic acid derivatives Grant 7,098,241 - Grossmann , et al. August 29, 2	2006-08-29
Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors Grant 7,091,229 - Georges , et al. August 15, 2	2006-08-15
Antibodies against insulin-like growth factor 1 receptor and uses thereof App 20050008642 - Graus, Yvo ; et al.	2005-01-13
Antibodies against insulin-like growth factor 1 receptor and uses thereof App 20040228859 - Graus, Yvo ; et al.	2004-11-18
Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors Grant 6,800,638 - Georges , et al. October 5, 2	2004-10-05
Thiophene hydroxamic acid derivatives App 20040122079 - Grossmann, Adelbert ; et al.	2004-06-24
Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors App 20040077698 - Georges, Guy ; et al.	2004-04-22
Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors App 20040053960 - Georges, Guy ; et al.	2004-03-18
Antibodies against SEMP1(p23) Grant 6,627,439 - Hoevel , et al. September 30, 2	2003-09-30
Antibodies against SEMP1 (p23) App 20020150574 - Hoevel, Thorsten ; et al.	2002-10-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.